Literature DB >> 3368691

[Neurophysiological and therapeutic evaluation of stiripentol in epilepsy. Preliminary results].

P Loiseau1, E Strube, J Tor, R H Levy, C Dodrill.   

Abstract

The main objective of this study was to determine whether stripentol (STP) alleviates side-effects commonly observed in treated epileptic patients, since preliminary data suggested a positive psychotropic effect. A secondary objective was an evaluation of drug efficacy. Eleven patients with either a drug-resistant epilepsy or toxic effects of AEDs completed the study. Ten had symptomatic partial epilepsies and one an idiopathic generalized epilepsy. STP was added to the baseline therapy (1 or 2 AEDs) and the dose of the baseline AEDs was reduced to maintain plasma levels unchanged (mean reduction: PB 26%, PHT: 49%, CBZ: 38%). Several motor, perceptual and attention tasks and the Washington Psychosocial Seizure Inventory were performed before and after STP administration. Seizure frequency and clinical side-effects were evaluated during a baseline period and after two months of constant therapy. Effects of repeated administration of the neuropsychological battery were assessed by administration of the battery on two occasions at 12-week interval to a randomized subgroup of patients. No practice effect was observed. A trend of improvement (p less than 0.05) in the performance of two tasks requiring sustained attention was noted. Previous side-effects (mainly drowsiness) decreased or disappeared in 7 of 9 patients who became more alert. Six of the nine uncontrolled patients experienced a decrease in seizure frequency equal to or larger than 50 per cent.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3368691

Source DB:  PubMed          Journal:  Rev Neurol (Paris)        ISSN: 0035-3787            Impact factor:   2.607


  6 in total

Review 1.  Stiripentol add-on therapy for drug-resistant focal epilepsy.

Authors:  Francesco Brigo; Stanley C Igwe; Nicola Luigi Bragazzi
Journal:  Cochrane Database Syst Rev       Date:  2022-09-06

Review 2.  The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on topiramate, zonisamide and tiagabine.

Authors:  E Perucca; M Bialer
Journal:  Clin Pharmacokinet       Date:  1996-07       Impact factor: 6.447

Review 3.  Newer antiepileptic drugs. Towards an improved risk-benefit ratio.

Authors:  P N Patsalos; J W Sander
Journal:  Drug Saf       Date:  1994-07       Impact factor: 5.606

Review 4.  New anticonvulsant drugs. Focus on flunarizine, fosphenytoin, midazolam and stiripentol.

Authors:  M Bebin; T P Bleck
Journal:  Drugs       Date:  1994-08       Impact factor: 9.546

Review 5.  Stiripentol add-on therapy for focal refractory epilepsy.

Authors:  Francesco Brigo; Stanley C Igwe; Nicola Luigi Bragazzi
Journal:  Cochrane Database Syst Rev       Date:  2018-05-10

6.  Stiripentol add-on therapy for drug-resistant focal epilepsy.

Authors:  Francesco Brigo; Stanley C Igwe; Nicola Luigi Bragazzi
Journal:  Cochrane Database Syst Rev       Date:  2020-05-26
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.